Transfusion-transmitted cytomegalovirus infection

Area of Science:

• Infectious Diseases
• Hematology
• Transfusion Medicine

Background:

• Transfusion-associated cytomegalovirus (CMV) infections cause significant illness and death in immunocompromised, seronegative individuals.
• Current strategies like seronegative blood products reduce infection rates to under 7%.

Purpose of the Study:

• To evaluate filtered blood as a potential alternative to seronegative blood products for preventing transfusion-associated CMV infections.
• To highlight the undefined clinical significance of secondary CMV strain infections.

Main Methods:

• The study reviews existing data on transfusion-associated CMV infections.
• It compares the efficacy of seronegative blood products versus filtered blood in preventing CMV transmission.
• It discusses the implications of different CMV strains in transfusion recipients.

Main Results:

• Seronegative blood products are effective, reducing CMV infection incidence to less than 7%.
• Filtered blood shows promise as an alternative strategy for CMV prevention in transfusion settings.
• The clinical impact of acquiring a second CMV strain post-transfusion requires further investigation.

Conclusions:

• Filtered blood may serve as a viable alternative to seronegative blood for preventing transfusion-associated CMV infections.
• Further research is needed to clarify the clinical relevance of secondary CMV strain infections in transfusion recipients.